| [1] |
WANG Huilin, JIANG Wei, YU Qitao.
Progress in the application of patient?reported outcomes in tumor immunotherapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 255-260.
|
| [2] |
LIU Yan, JIA Yuxian, LI Tingting.
Research progress of cytokine release syndrome due to tumor immunotherapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(5): 575-580.
|
| [3] |
WANG Binru, CHEN Shiming.
Research progress on explosive tumor progression induced by targeted PD-1 and PD-L1 immunotherapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(2): 218-223.
|
| [4] |
DU Cheng, JIN Shanxiu, XIE Xiaodong.
A discussion of the influencing factors of the efficacy of tumor immune checkpoint inhibitors： from the micro to the macro
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(6): 575-584.
|
| [5] |
BAI Rilan, CUI Jiuwei.
Predictors of immunotherapy efficacy from the perspective of tumor immune microenvironment
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(6): 585-593.
|
| [6] |
ZHU Jinghan, LIANG Yuanzheng, WANG Liang.
Challenges and solutions of CAR-T cell therapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(6): 594-601.
|
| [7] |
ZHENG Fang, XIE Xiaodong.
Current status and research progress of diagnosis and treatment of tumor immune-related hypophysitis
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(6): 602-606.
|
| [8] |
CUI Zhaolei, CHEN Yan.
Research progress of cancer/testis antigen as a target of tumor immunotherapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(3): 250-256.
|
| [9] |
FU Junjiang, XIAO Ting.
Opportunities and challenges of circular RNA in tumor epigenetics
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(3): 257-262.
|
| [10] |
ZHANG Xiaoyu , XIE Xiaodong.
How far is tumor immunotherapy from the path of precision medicine
[J]. Chinese Journal of Oncology Prevention and Treatment, 2019, 11(2): 89-92.
|
